Related Experiment Video
Updated: Jun 10, 2026
Povidone Iodine Rectal Preparation at Time of Prostate Needle Biopsy is a Simple and Reproducible Means to Reduce Risk of Procedural Infection
Published on: September 21, 2015
Short-Term Daily Vonoprazan Treatment Is More Commonly Associated With Infectious Gastroenteritis Than Short-Term
Zaid Al-Fakhouri1, Benjamin Douglas Xun Liu2, Laith AlOmari3
1Department of Medicine, MetroHealth Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
Background:
Proton pump inhibitors (PPIs) are linked to various short-term and long-term side effects. Vonoprazan, a potassium-competitive acid blocker, was recently introduced into the US market. This study aims to compare the reported short-term adverse effects of PPIs versus vonoprazan.
Methods:
Using TriNetX, we identified a global cohort from 14 countries of first-time vonoprazan or PPI users after November 1, 2023. Vonoprazan users could not have been on a PPI for at least 6 months before initiation. PPI users could not have used vonoprazan. Groups were matched for demographics, comorbidities, and medication use. Kaplan-Meier and Cox proportional hazards models estimated complication risks within 90 days.
Results:
After propensity score matching, 11,851 patients were included in both cohorts, with average follow-up of 66 days in the vonoprazan group and 60 days in the PPI group. Mean age was 62.3 ± 17.5 years and 62.9 ± 17.7 years, respectively, and most patients were female (58.7% vs. 60.3%, respectively). Within 90 days, vonoprazan users in the global cohort had a higher risk of infectious gastroenteritis than PPI users (HR 2.06; 95% CI 1.37-3.10). In GERD patients, vonoprazan users were at higher risk of infectious gastroenteritis than PPI users (HR 3.00; 95% CI 1.64-5.48), while US-only patients had insufficient number of cases for the comparison. No differences were observed for pneumonia, iron deficiency, and B12 deficiency between both groups.
Conclusion:
Vonoprazan was associated with an increased risk of infectious gastroenteritis within 90 days after drug initiation compared to PPIs.
Related Concept Videos
01:26Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current medication...
01:16Treating Helicobacter pylori in Peptic Ulcers: Antimicrobial Therapy
01:13Acid Suppressive Drugs for Peptic Ulcer Disease: Proton Pump Inhibitors
Gastric acid, a potent cocktail of hydrogen and chloride ions, is produced in specialized parietal cells within the...
01:17Drugs for Treatment of Diarrhea-Predominant IBS
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
01:30Peptic Ulcer Disease I: Introduction
An acute ulcer, marked by superficial erosion and minimal inflammation, swiftly resolves upon identifying and addressing the underlying cause. In contrast, a chronic ulcer persists, potentially eroding through the muscular wall and forming fibrous tissue.
Peptic ulcers can also be...
01:25Peptic Ulcer Disease I: Introduction